Description
Vitrakvi (larotrectinib) is an oral solution that inhibits tropomyosin receptor kinases, prescribed for certain cancers with NTRK gene fusions. It's a 20 mg/mL concentrate manufactured by Bayer HealthCare Pharmaceuticals Inc. and approved under NDA211710 in December 2022. This information was generated using AI and is provided for informational and research purposes only.
Resources
| Name |
Format |
Description |
Link |
|
21 |
Access the FDA dataset for Larotrectinib — ANDA 211710 submitted by Mylan Institutional LLC
|
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211710 |
Tags
- drug-safety
- health-care
- public-health
- pharmaceuticals
- medications